Acute Respiratory Distress Syndrome (ARDS) Market Report 2026

The acute respiratory distress syndrome (ards) market size has grown rapidly in recent years. It will grow from $1.41 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to rising incidence of respiratory infections, growing hospital icu infrastructure, increasing awareness of ards management protocols, limited availability of advanced ventilation devices, adoption of supportive care practices.

The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to technological advancements in mechanical ventilation and ecmo systems, increasing r&d in ards therapeutics, expansion of critical care units globally, rising investment in personalized patient management solutions, growing prevalence of severe pneumonia and sepsis. Major trends in the forecast period include rising adoption of mechanical ventilation and ecmo devices, increasing prevalence of ards due to COVID-19 and other respiratory diseases, growing use of advanced diagnostic tests for early detection, expansion of critical care and icu facilities, focus on personalized and supportive care management.

The increasing number of respiratory illnesses is expected to drive the growth of the acute respiratory distress syndrome (ARDS) market going forward. Respiratory illnesses are a group of medical conditions affecting the respiratory system, including the lungs and airways, often causing difficulty in breathing. The rising incidence of respiratory illnesses, such as COVID-19, is a key factor fueling the growth of the acute respiratory distress syndrome (ARDS) market. As more individuals develop respiratory illnesses, the demand for ARDS therapies and treatments is likely to rise, contributing to market expansion. For instance, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, Australia recorded a total of 474 asthma-related deaths in 2023, including 325 females and 149 males. This figure is nearly identical to the 473 asthma-related deaths reported in 2022, indicating a consistent trend in asthma-related mortality over the two years. Therefore, the increasing number of respiratory illnesses is propelling the growth of the acute respiratory distress syndrome (ARDS) market.

Major companies operating in the acute respiratory distress syndrome market are focusing on developing advanced immune modulators to improve patient survival and reduce inflammation. Immune modulators are therapies that restore immune balance by targeting dysfunctional inflammatory pathways without suppressing overall immune function. For instance, in June 2025, BioAegis Therapeutics, a US-based clinical-stage company, received FDA Fast Track designation for its lead product, recombinant human plasma gelsolin (rhu-pGSN), for the treatment of ARDS. The therapy works by replenishing gelsolin, a key immune regulatory protein, to modulate NLRP3 inflammasome activation, enhance microbial clearance, remove toxic actin and inflammatory mediators, and regulate macrophage activity. rhu-pGSN is being evaluated in a 600-patient global Phase 2b trial for moderate to severe ARDS and may also be made available through the FDA Expanded Access or Compassionate Use program. The Fast Track designation allows for accelerated regulatory interactions, rolling review of marketing applications, and eligibility for priority review, potentially speeding its time to market and providing a novel therapeutic option for patients with limited alternatives.

In April 2024, Healios K.K., a Japan-based regenerative medicine-focused biotech company, acquired all assets of Athersys, Inc., including its off-the-shelf stem cell therapy MultiStem (invimestrocel), through a credit bid of approximately $2.25 million. This acquisition gives Healios full control of the MultiStem intellectual property and R&D capabilities, enabling further global development of the therapy, particularly for acute respiratory distress syndrome (ARDS). Athersys, Inc. is a US-based provider of therapies for acute respiratory distress syndrome.

Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy.

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute respiratory distress syndrome (ards) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the ARDS market by increasing the cost of imported mechanical ventilators, ECMO devices, and diagnostic equipment used in critical care. Segments such as mechanical ventilation and ECMO treatment devices are most impacted, with regions including North America, Europe, and Asia-Pacific facing higher import duties and supply chain disruptions. While tariffs have raised production and procurement costs, they have also encouraged local manufacturing, innovation in ventilator technologies, and regional self-sufficiency in critical care equipment.

The acute respiratory distress syndrome (ards) market research report is one of a series of new reports that provides acute respiratory distress syndrome (ards) market statistics, including acute respiratory distress syndrome (ards) industry global market size, regional shares, competitors with a acute respiratory distress syndrome (ards) market share, detailed acute respiratory distress syndrome (ards) market segments, market trends and opportunities, and any further data you may need to thrive in the acute respiratory distress syndrome (ards) industry. This acute respiratory distress syndrome (ards) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute respiratory distress syndrome (ARDS) is a potentially life-threatening condition characterized by stiff, non-compliant lungs and low oxygen levels. It is an acute, diffuse, and inflammatory form of lung injury that can develop in critically ill patients. Treatment for acute respiratory distress syndrome (ARDS) involves mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygenation and prevent further lung damage.

The main types of services for acute respiratory distress syndrome (ARDS) are diagnosis and treatment. Diagnosis involves distinguishing a disease or disorder from other potential conditions and determining its nature. ARDS is diagnosed based on physical examination, chest X-rays, and oxygen measurements. It can result from causes such as COVID-19, sepsis, inhalation of harmful substances, severe pneumonia, and others, with severity classified as mild, moderate, or severe. The primary end users include hospitals, clinics, ambulatory service centers, and others.

The acute respiratory distress syndrome (ARDS) market includes revenues earned by entities by providing resolution and recovery services, medication, supplemental oxygen and mechanical ventilation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute respiratory distress syndrome (ARDS) market consists of sales of neuromuscular blockers, corticosteroids, monitoring devices, diagnostic devices and therapeutic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.